SBIR Phase I: A Novel SARS-CoV-2 Virus-Like Particle Optimized to Deliver shRNA Therapeutics to Prevent and Treat Infection (COVID-19)

SBIR 第一阶段：一种新型 SARS-CoV-2 病毒样颗粒，经过优化可提供 shRNA 疗法来预防和治疗感染 (COVID-19)

• 批准号: 2051972
• 负责人: Michelle Ngai
• 金额: $ 24.67万
• 依托单位: NANORED LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-03-01 至 2022-04-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2051972&HistoricalAwards=false
• 关键词: SBIR; Phase; Novel; SARS; CoV

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project involves generation of a new class of therapeutics to combat the COVID-19 pandemic, while also laying the foundation for a new way to treat respiratory infection and pulmonary illness. This approach relies on precise delivery of a treatment that impairs the ability of the COVID-19 virus to form infectious particles. In the future, this approach could be rapidly modified for use against other respiratory viruses or to deliver other pulmonary medicines. This Small Business Innovation Research (SBIR) Phase I project seeks to generate a novel SARS-CoV-2 therapeutic through precise delivery of a genomic medicine and direct competition with the SARS-CoV-2 virus for access to at-risk or infected pulmonary epithelial cells. This project will use an in silico approach to design and prioritize the product, followed by in vitro testing and validation. This project aims to prioritize a novel delivery vehicle and genomic medicine candidate.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）第一阶段项目的更广泛影响/商业潜力涉及产生一种新的治疗方法来对抗COVID-19大流行，同时也为治疗呼吸道感染和肺部疾病的新方法奠定基础。这种方法依赖于精确提供治疗，从而削弱COVID-19病毒形成传染性颗粒的能力。在未来，这种方法可以快速修改用于对抗其他呼吸道病毒或提供其他肺部药物。这个小企业创新研究（SBIR）第一阶段项目旨在通过精确递送基因组药物并与SARS-CoV-2病毒直接竞争获得风险或感染的肺上皮细胞来产生新的SARS-CoV-2治疗药物。本项目将使用计算机模拟方法设计产品并确定其优先级，然后进行体外测试和确认。该项目旨在优先考虑一种新的运载工具和基因组药物候选人。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。